Scoop has an Ethical Paywall
Acrux Recognized by AusBiotech for Excellence
Wednesday 28 October 2009
FOR IMMEDIATE
RELEASE
Melbourne-based biotech Acrux was today recognised for its excellence within the Australian biotechnology sector, with CEO Richard Treagus accepting the AusBiotech –Roche 2009 Excellence Award for outstanding contribution to the biotechnology industry by a company at the AusBiotech 2009 conference this morning.
Acrux
recently announced excellent trial results for their product
Axiron, marking a resounding success for the company, its
shareholders and more broadly for the Australian
biotechnology sector.
Acrux’s announcement of
successful Phase III results for Axiron makes it one of a
small number of Australian companies to have achieved this
milestone. Axiron is in development as the first medicine
of its kind to treat men with testosterone deficiency, and
is applied to the underarm in a similar way to a
deodorant.
“It is wonderful to see an Australian
company and AusBiotech member leading in this way and proves
that an Australian company has the capacity and capability
to take a product to Phase III on its own,” said Dr Anna
Lavelle, CEO of AusBiotech.
AusBiotech is the national body for the biotechnology and life sciences industry, hosting AusBiotech 2009 – the premier Australasian biotechnology conference from 27 – 30 October in Melbourne.
ENDS
Global Jews for Palestine: Call From Jewish Groups Across The Globe: Tell Your Political Representatives Now- UNRWA Is Urgent
Save The Children: GAZA - New Year Begins With More Children Killed By Israeli Airstrikes
OHCHR: UN High Commissioner For Human Rights Volker Türk On Abolition Of Death Penalty In Zimbabwe
APEC: Building A Sustainable Tomorrow - APEC Returns To Korea After 20 Years
Aotearoa Healthcare Workers For Palestine: Wellington Healthcare Workers Demanding Overdue Government Action On Renewed Brutal Israeli Attacks On Gaza
WHO: WHO Continues To Urge China To Share Data Five Years After COVID-19